| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
|
Purity: ≥98%
SRT3109 (SRT-3109) is a novel and potent antagonist of CXCR2 (C-X-C chemokine receptor type 2) with potential anti-Inflammatory and immunomodulatory activity. It is used in the study of chemokine-mediated diseases and inhibits CXCR2 with a pIC50 of 8.2. Integral membrane proteins called CXCRs, or CXC chemokine receptors, are selectively bind to and react to members of the CXC chemokine family of cytokines. Seven transmembrane (7-TM) proteins, so named because they span the cell membrane seven times, are a large family of G protein-linked receptors that comprise one subfamily of chemokine receptors. CXCR1 through CXCR7 are the seven CXC chemokine receptors that are currently recognized in mammals. The CXC motif of CXC chemokines that have an E-L-R amino acid motif right next to it are recognized by the closely related receptors CXCR1 and CXCR2.
| Targets |
CXCR2 ( pIC50 = 8.2 )
|
|---|---|
| ln Vitro |
SRT3109 (Example 1) is a CXCR2 antagonist that is used in the study of chemokine-mediated diseases. It has a pIC50 of 8.2.[1]
|
| References |
| Molecular Formula |
C18H23F2N5O4S2
|
|
|---|---|---|
| Molecular Weight |
475.53
|
|
| Exact Mass |
475.115
|
|
| Elemental Analysis |
C, 45.46; H, 4.88; F, 7.99; N, 14.73; O, 13.46; S, 13.48
|
|
| CAS # |
1204707-71-0
|
|
| Related CAS # |
|
|
| PubChem CID |
44602493
|
|
| Appearance |
White to off-white solid powder
|
|
| Density |
1.6±0.1 g/cm3
|
|
| Boiling Point |
726.6±70.0 °C at 760 mmHg
|
|
| Flash Point |
393.3±35.7 °C
|
|
| Vapour Pressure |
0.0±2.5 mmHg at 25°C
|
|
| Index of Refraction |
1.661
|
|
| LogP |
2.07
|
|
| Hydrogen Bond Donor Count |
4
|
|
| Hydrogen Bond Acceptor Count |
12
|
|
| Rotatable Bond Count |
10
|
|
| Heavy Atom Count |
31
|
|
| Complexity |
670
|
|
| Defined Atom Stereocenter Count |
2
|
|
| SMILES |
FC1=C(F)C=CC=C1CSC2=NC(NS(=O)(N3CCC3)=O)=CC(N[C@@H]([C@@H](O)CO)C)=N2
|
|
| InChi Key |
QVKPEMXUBULFBM-RISCZKNCSA-N
|
|
| InChi Code |
InChI=1S/C18H23F2N5O4S2/c1-11(14(27)9-26)21-15-8-16(24-31(28,29)25-6-3-7-25)23-18(22-15)30-10-12-4-2-5-13(19)17(12)20/h2,4-5,8,11,14,26-27H,3,6-7,9-10H2,1H3,(H2,21,22,23,24)/t11-,14+/m1/s1
|
|
| Chemical Name |
N-[2-[(2,3-difluorophenyl)methylsulfanyl]-6-[[(2R,3R)-3,4-dihydroxybutan-2-yl]amino]pyrimidin-4-yl]azetidine-1-sulfonamide
|
|
| Synonyms |
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.75 mg/mL (5.78 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 27.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.75 mg/mL (5.78 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 27.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.75 mg/mL (5.78 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1029 mL | 10.5146 mL | 21.0292 mL | |
| 5 mM | 0.4206 mL | 2.1029 mL | 4.2058 mL | |
| 10 mM | 0.2103 mL | 1.0515 mL | 2.1029 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA